Oncotarget
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases.The term was introduced in the inaugural Editorial,Introducing Oncotarget.
As of January 1, 2022,Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Post-Publication Promotion
Learn about ourFREE
Impact Journals, LLC is the publisher of Oncotarget:www.impactjournals.com.
Impact Journals is a member of theWellcome Trust List of Compliant Publishers.
Impact Journals is a member of theSociety for Scholarly Publishing.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.This malicious action will be reported to the FBI.
Current Volume
This Month's Popular DOIs
(Crossref resolutions)
| 10.18632/ONCOTARGET.23208 |
| 10.18632/ONCOTARGET.6429 |
| 10.18632/ONCOTARGET.9859 |
| 10.18632/ONCOTARGET.13553 |
| 10.18632/ONCOTARGET.14401 |
| 10.18632/ONCOTARGET.15422 |
| 10.18632/ONCOTARGET.16407 |
| 10.18632/ONCOTARGET.19087 |
Most popular Oncotarget DOIs, measured by the number of times each DOI was successfully resolved.
Most Popular DOIs Published in 2024
(Crossref Data)
Top-10 Most Popular DOIs of 2024
(Crossref Data)
Milestones in Modern Scholarly Publishing
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025.Learn more here andhere.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds.Learn more.
Oncotarget.org: Blog Posts on
New & Trending Papers
Oncotarget.net: Latest Insights
From Our Authors
Volume 3, Issue 2
February 2012
About The Cover
PRL-3 chimeric mAb recognizes EGFP-PRL-3 overexpressed in DLD-1 human colorectal cancer cells by indirect immunofluorescence. Shown is the composite image of EGFP-PRL-3 in fixed DLD-1 cells (green) and PRL-3 chimeric antibody together with an image of anti-human IgG Texas-Red (red) to reveal the binding to PRL-3 protein. See Guo et al.
Table of Contents
Editorial Comments
| c-MYC and SIRT1 locked in a vicious cycle |
https://doi.org/10.18632/oncotarget.440 Antje Menssen, and Heiko Hermeking |
| 112-113 |
| Abstract | PDF | HTML | How to cite |
| Modulating Mesothelin Shedding to Improve Therapy |
https://doi.org/10.18632/oncotarget.445 Ira Pastan, and Yujian Zhang |
| 114-115 |
| PDF | HTML | How to cite |
| Bryostatin analog: improving on Nature’s design |
https://doi.org/10.18632/oncotarget.460 Dale Boger |
| 116-117 |
| Abstract | PDF | HTML | How to cite |
Reviews
| Targeting Mnks for Cancer Therapy |
https://doi.org/10.18632/oncotarget.453 Jinqiang Hou,Frankie Kam,Christopher G Proud, and Shudong Wang |
| 118-131 |
| Abstract | PDF | HTML | How to cite |
Brief Reports
| Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. |
https://doi.org/10.18632/oncotarget.447 Elena Martynova,Silvia Pozzi,Valentina Basile,Diletta Dolfini,Federico Zambelli,Carol Imbriano,Giulio Pavesi, and Roberto Mantovani |
| 132-143 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
Research Papers
| Ras inhibition by FTS attenuates brain tumor growth in mice directly and by enhancing reactivity of cytotoxic lymphocytes |
https://doi.org/10.18632/oncotarget.420 Elizabeta Aizman,Adi Mor,Ayelet Levy,Jacob George, and Yoel Kloog |
| 144-157 |
| Abstract | PDF | HTML | How to cite |
| Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice |
https://doi.org/10.18632/oncotarget.442 Ke Guo,Jing Ping Tang,Jie Li,Cheng Peow Tan,Abdul Qader O. Al-Aidaroos,Cheng William Hong,Leyon Varghese,Zhi Wei Feng,Jung Eun Park,Jian Biao Zhou,Wee Joo Chng, and Qi Zeng |
| 158-171 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| Single Enantiomer of YK-4-279 Demonstrates Specificity in Targeting the Oncogene EWS-FLI1 |
https://doi.org/10.18632/oncotarget.454 Julie S. Barber-Rotenberg,Saravana P. Selvanathan,Yali Kong,Hayriye V. Erkizan,Tara M. Snyder,S. Peter Hong,Christina L. Kobs,Natalie L. South,Steven Summer,Philip J. Monroe,Maksymilian Chruszcz,Veselin Dobrev,Perrer N. Tosso,Lauren J. Scher,Wladek Minor,Milton L. Brown,Steven J. Metallo,Aykut Üren, and Jeffrey A. Toretsky |
| 172-182 |
| Abstract | PDF | HTML | How to cite |
| Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor |
https://doi.org/10.18632/oncotarget.449 Natalya V. Guseva,Oskar W. Rokhlin,Thomas B. Bair,Rebecca B. Glover, and Michael B. Cohen |
| 183-194 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
Research Perspectives
| MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia |
https://doi.org/10.18632/oncotarget.448 Carlo Maria Croce,Rosa Visone,Angelo Veronese, and Veronica Balatti |
| 195-202 |
| Abstract | PDF | HTML | How to cite |
| Novel targeted therapies for mantle cell lymphoma |
https://doi.org/10.18632/oncotarget.426 Lapo Alinari,Beth Christian, and Robert Baiocchi |
| 203-211 |
| Abstract | PDF | HTML | How to cite |
Methodological Reports
| A Gene Expression Profile Test for the Differential Diagnosis of Ovarian Versus Endometrial Cancers |
https://doi.org/10.18632/oncotarget.450 Anita Lal,Rebecca Panos,Mira Marjanovic,Michael Walker,Eloisa Fuentes,Daniel S. Kapp,W David Henner,Ljubomir J. Buturovic, and Meredith Halks-Miller |
| 212-223 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
Copyright © 2025 Rapamycin Press LLC dba Impact Journals